Literature DB >> 32048361

Engineering Stimuli-Activatable Boolean Logic Prodrug Nanoparticles for Combination Cancer Immunotherapy.

Bo Hou1,2, Lei Zhou1, Hui Wang2, Madiha Saeed1, Dangge Wang1, Zhiai Xu3, Yaping Li1, Haijun Yu1.   

Abstract

Prodrug nanoparticles that codeliver the immune modulators to the tumor site are highly recommendable for cancer immunotherapy yet remain challenging. However, effective stimuli-responsive strategies that exploit the endogenous hallmarks of the tumor have paved the way for cancer immunotherapy. For the first time, the development of the Boolean logic prodrug nanoparticles (BLPNs) for tumor-targeted codelivery of immune modulators (e.g., immune activator and immune inhibitor) and combination immunotherapy is reported herein. A library of stimuli-activatable BLPNs is fabricated yielding YES/AND logic outputs by adjusting the input combinations, including extracellular matrix metalloproteins 2/9 (MMP-2/9), intracellular acidity (pH = 5.0-6.0), and reduction (glutathione) in the tumor microenvironment. Tunable and selective control over BLPNs dissociation and prodrug activation is achieved by specifying the connectivity of orthogonal stimuli-labile spacers while exploiting the endogenous signals at the tumor sites. The tumor-specific distribution of the BLPNs and stimuli-activation of the immune modulators for highly efficient cancer immunotherapy are further demonstrated. The results reported in this study may open a new avenue for tumor-specific delivery of immune therapeutics and precise cancer immunotherapy.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Boolean logic gates; cancer immunotherapy; prodrug nanoparticles; stimuli activation; tumor microenvironment

Year:  2020        PMID: 32048361     DOI: 10.1002/adma.201907210

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  15 in total

Review 1.  Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.

Authors:  Wen-Lu Yan; Tian-Qun Lang; Wen-Hui Yuan; Qi Yin; Ya-Ping Li
Journal:  Acta Pharmacol Sin       Date:  2022-09-01       Impact factor: 7.169

Review 2.  Supramolecular nanomedicines through rational design of self-assembling prodrugs.

Authors:  Han Wang; Maya Monroe; Faith Leslie; Charles Flexner; Honggang Cui
Journal:  Trends Pharmacol Sci       Date:  2022-04-19       Impact factor: 17.638

Review 3.  New Advances in Nano-Drug Delivery Systems: Helicobacter pylori and Gastric Cancer.

Authors:  Xiang Zhu; Tingting Su; Shouhua Wang; Huiqing Zhou; Weibin Shi
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

4.  Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity.

Authors:  Qichao Yang; Xianbin Ma; Yao Xiao; Tian Zhang; Leilei Yang; Shaochen Yang; Mengyun Liang; Shuo Wang; Zhizhong Wu; Zhigang Xu; Zhijun Sun
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

5.  Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma.

Authors:  Jiao Xue; Yining Zhu; Shuting Bai; Chunting He; Guangsheng Du; Yuandong Zhang; Yao Zhong; Wenfei Chen; Hairui Wang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2021-12-01       Impact factor: 14.903

6.  A Molecular Logic Gate for Developing "AND" Logic Probes and the Application in Hepatopathy Differentiation.

Authors:  Mengqi Chen; Chunhong Wang; Zexuan Ding; Hao Wang; Yu Wang; Zhibo Liu
Journal:  ACS Cent Sci       Date:  2022-06-06       Impact factor: 18.728

Review 7.  Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.

Authors:  Bin Ji; Minjie Wei; Bin Yang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

Review 8.  Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.

Authors:  Jing Gao; Wei-Qi Wang; Qing Pei; Megan S Lord; Hai-Jun Yu
Journal:  Acta Pharmacol Sin       Date:  2020-04-21       Impact factor: 6.150

Review 9.  Nanoparticulation of Prodrug into Medicines for Cancer Therapy.

Authors:  Yuezhou Zhang; Huaguang Cui; Ruiqi Zhang; Hongbo Zhang; Wei Huang
Journal:  Adv Sci (Weinh)       Date:  2021-07-29       Impact factor: 16.806

Review 10.  Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy.

Authors:  Fangmin Chen; Yifan Fang; Xiang Chen; Rui Deng; Yongjie Zhang; Jingwei Shao
Journal:  Asian J Pharm Sci       Date:  2020-08-21       Impact factor: 6.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.